Covid-19 Vaccine Update

Kirsty Blackman Excerpts

Thursday 4th February 2021 Commons Chamber

[Nadhim Zahawi]

There is no one who wants to see the economy open and functioning as soon as possible more than my right hon. Friend and the Prime Minister. As my right hon. Friend the Member for Forest of Dean (Mr Harper) rightly points out, the deadline for the top four cohorts is the middle of February. If we go forward three weeks from there, that is when the protection of the two vaccines really kicks in. The plan is to reopen schools on 8 March, after which we will gradually reopen the economy. It is important also to wait for the evidence. As I said earlier, the Vivaldi study and the SIREN study will enable us to see the impact of the vaccines on infection rates and on transmission. We are getting some really positive data from Israel and, of course, from the Oxford team. That will be our own robust evidence and, as the Prime Minister said, we will then share with the House on 22 February the roadmap of how we intend very gradually to reopen the economy.

[Kirsty Blackman (Aberdeen North) (SNP) [V]]

The UK Government have pre-purchased 300 million doses for a population of 66 million. Guinea, a low-income country, has received only 55 doses for its entire population. Given that COVAX will cover only about 20% of the population in low and middle-income countries, can the Minister explain how the UK will step up and take part as global Britain, ensuring that those people in low and middle-income countries and developing countries are able to access the vaccine?

[Nadhim Zahawi]

I am grateful to the hon. Lady for her question. We will do so in a couple of ways. First, once we have enough vaccine supply to be able to offer the vaccine to every adult in the United Kingdom—every eligible group from 1 to 9 and then phase 2—we will then look at our vaccine supply strategy. At the moment, we are nowhere near having enough supply to be able to make that offer. That has to be our priority. She mentions COVAX, but that is only part of the story for us in the United Kingdom. We have put about £450 million-plus into COVAX, but a total of £1.3 billion into the vaccine initiative of GAVI, the Vaccine Alliance. We are, I think, the largest donor, not only in money but per capita. We are making a big, big impact globally in both research and development, and vaccinations to low and middle-income countries.